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Abstract
Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric cancer population.
Survival among metastatic RMS patients has remained dismal yet unimproved for years. We previously identified the class
I-specific histone deacetylase inhibitor, entinostat (ENT), as a pharmacological agent that transcriptionally suppresses the
PAX3:FOXO1 tumor-initiating fusion gene found in alveolar rhabdomyosarcoma (aRMS), and we further investigated the
mechanism by which ENT suppresses PAX3:FOXO1 oncogene and demonstrated the preclinical efficacy of ENT in RMS
orthotopic allograft and patient-derived xenograft (PDX) models. In this study, we investigated whether ENT also has
antitumor activity in fusion-negative eRMS orthotopic allografts and PDX models either as a single agent or in combination
with vincristine (VCR).
Methods: We tested the efficacy of ENT and VCR as single agents and in combination in orthotopic allograft and PDX
mouse models of eRMS. We then performed CRISPR screening to identify which HDAC among the class I HDACs is
responsible for tumor growth inhibition in eRMS. To analyze whether ENT treatment as a single agent or in combination
with VCR induces myogenic differentiation, we performed hematoxylin and eosin (H&E) staining in tumors.
Results: ENT in combination with the chemotherapy VCR has synergistic antitumor activity in a subset of fusion-
negative eRMS in orthotopic “allografts,” although PDX mouse models were too hypersensitive to the VCR dose
used to detect synergy. Mechanistic studies involving CRISPR suggest that HDAC3 inhibition is the primary
mechanism of cell-autonomous cytoreduction in eRMS. Following cytoreduction in vivo, residual tumor cells in
the allograft models treated with chemotherapy undergo a dramatic, entinostat-induced (70–100%) conversion to
non-proliferative rhabdomyoblasts.
Conclusion: Our results suggest that the targeting class I HDACs may provide a therapeutic benefit for selected
patients with eRMS. ENT’s preclinical in vivo efficacy makes ENT a rational drug candidate in a phase II clinical trial
for eRMS.
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Background
Rhabdomyosarcoma (RMS) is among the most common
causes of death in pediatric population with cancer.
RMS is comprised of two main histological subtypes,
embryonal RMS (eRMS) and alveolar RMS (aRMS) with
eRMS comprising half of all RMS cases [1]. The cells of
eRMS are reminiscent of myogenic precursors delamin-
ating from the lateral dermomyotome of a human 6- to
8-week-old embryo [2]. eRMS exhibits 11p15 loss of het-
erozygosity [3, 4] and/or mutations in the components
of RAS pathway including NRAS, KRAS, HRAS, FGFR4,
PIK3CA, CTNNB1, FBXW7, and BCOR [5, 6]. Metastatic
RMS patients have the poorest prognosis, with no im-
provements in outcome in 46 years [7–9]. The long-term
survival rate for metastatic eRMS is 40% [7, 9–12].
With the addition of a targeted therapy, short-term
survival in relapsed RMS is improving measurably; not-
ably, the ARST0921 Children’s Oncology Group (COG)
clinical trial for relapsed RMS was stopped early. The
6-month event-free survival (EFS) for temsirolimus plus
vinorelbine and cyclophosphamide chemotherapy was
superior to the 6-month EFS for bevacizumab plus the
same chemotherapy (65% vs 50%, two-sided p value =
0.0031) [13]. The next task is to determine whether
these stepwise changes in 6-month EFS will result in im-
provements over chemotherapy-only long-term survival
rates for metastatic aRMS and eRMS [1, 3]. Neverthe-
less, other new agents are also needed.
Our recent study established the antitumor efficacy of
class I-specific histone deacetylase (HDAC) inhibitor,
entinostat (ENT) with the chemotherapy, vincristine
(VCR) in preclinical cell and mouse models and found
HDAC3 inhibition as the primary mechanism of de-
creasing PAX3:FOXO1 expression in fusion positive
aRMS [14]. Herein, we demonstrate that ENT in com-
bination with the chemotherapy VCR has synergistic an-
titumor activity in a orthotopic fusion-negative eRMS
mouse model although our studies of patient-derived
xenograft (PDX) mouse models had too strong of VCR
single-agent activity to detect synergy. Mechanistic stud-
ies involving CRISPR suggest that HDAC3 inhibition is
the primary mechanism of cell-autonomous cytoreduc-
tion in eRMS. Our findings demonstrate that targeting
class I HDACs using ENT is a novel, clinically feasible
epigenetic therapy for children with fusion-negative
eRMS—a result which is in line with our parallel studies
in fusion-positive RMS [14].
Methods
Cell culture
Murine primary tumor cell cultures U57810 and U37125
were generated as described previously [15]. Briefly, for
the establishment of murine eRMS primary cell cultures,
tumor samples were minced into small fragments
followed by collagenase treatment (0.5%) overnight at 4 °
C. The disassociated cells were incubated in DMEM
supplemented with 10% fetal bovine serum (FBS) and
penicillin (100 U/mL)/streptomycin (100 μg/mL) in 5%
CO2 in air at 37 °C. Human eRMS RD and Rh18 cell
lines were cultured in RPMI 1640 growth medium sup-
plemented with 10% FBS and 1% penicillin/streptomycin
and incubated at 37 °C and 5% CO2. Primary Human
Skeletal Muscle Myoblasts (HSMM) were cultured in
growth medium (Cell Applications) supplemented with
10% FBS and 1% penicillin/streptomycin and incubated
at 37 °C and 5% CO2.
ENT treatment
HDAC inhibitor (HDACi): ENT (MS-275) was obtained
from Selleckchem (S1053).
RNA extraction and RT-PCR
For murine eRMS cell treatment studies, U57810 cells
were treated with VCR (2.5 nM), ENT (400 nM), or VCR
and ENT (2.5 nM and 400 nM, respectively) for 6 days.
RT-PCR was performed for Myoglobin, Myh1, MyoD,
and Myogenin relative to Gapdh using probes from
SYBR green (Thermo Fisher Scientific).
VCR: chemotherapy agent
VCR was obtained from Sigma (V8879).
siRNA-mediated knockdown of HDAC3
For silencing HDAC3, Rh30, RD, and HSMM cells were
transfected with 100 nM HDAC3 (L-003496-00-0005, 5
nmol) SMART pool siRNA reagent (a pool of four
siRNA duplexes all designed to target distinct sites
within the specific gene of interest) (Dharmacon) versus
scrambled siRNA (Dharmacon) using Lipofectamine
RNAimax (Invitrogen). siRNA lysates were subjected to
Western blotting using anti-HDAC3 antibody (Santa
Cruz Biotechnology).
Orthotopic allograft studies
Allograft studies were conducted with IACUC approval
at the Oregon Health & Science University. The orthoto-
pic allograft mouse model of eRMS (U57810, genotype
Myf5Cre, p53) was generated by injecting SCID Hairless
Outbred (SHO) mice at 8 weeks of age with cardiotoxin
in the right gastrocnemius muscle 1 day before injection
of 106 U57810 cells in the muscle. Treatment was started
once the tumors reached 0.25 cm3. Mice were treated
with ENT 5mg/kg/day by intraperitoneal (IP) injection,
VCR at a dose of 1 mg/kg weekly by IP injection, or in
combination at the same dose and treatment ended
when the tumors reached 1.5 cm3. During treatment,
mice with significant body weight loss approaching (10–
15%) were euthanized early per protocol.
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Patient-derived xenograft models at Champions Oncology
The Champions Personalized TumorgraftTM chemosen-
sitivity test was conducted using a TumorGraft model
established from a resection of sarcoma, which was re-
moved from the abdomen. “Chemosensitivity” test is
used for the patient drug sensitivity testing where we are
guiding patients’ clinical therapies by their PDX model
responses. In this instance, it is ENT +/− VCR testing.
The explant was received and immediately implanted
into immunodeficient mice for the purpose of propagat-
ing the tumor for the test. All test agents were formu-
lated according to the manufacturer’s specifications.
Beginning day 0, tumor dimensions were measured
twice weekly by a digital caliper and data, including indi-
vidual and mean estimated tumor volumes (mean TV ±
SEM), are recorded for each group. Tumor volume was
calculated using the formula: TV = width2 × length × π/
2. At study completion, percent tumor growth inhibition
(%TGI) values were calculated and reported for each
treatment group (T) versus control (C) using initial (i)
and final (f ) tumor measurements by the formula: %TGI
= [1 − (Tf − Ti)/(Cf − Ci)] × 100. Individual mice reporting
a tumor volume > 120% of the day 0 measurement are
considered to have progressive disease (PD). Individual
mice with neither sufficient shrinkage nor sufficient
tumor volume increases are considered to have stable
disease (SD). Individual mice reporting a tumor volume
≤ 70% of the day 0 measurement for two consecutive
measurements over a 7-day period are considered partial
responders (PR). If the PR persisted until study comple-
tion, percent tumor regression (%TR) is determined
using the formula: %TR = (1 − Tf/Ti) × 100; a mean value
is calculated for the entire treatment group. Individual
mice lacking palpable tumors for two consecutive mea-
surements over a 7-day period are classified as complete
responders (CR). All data collected in this study was
managed electronically and stored on a redundant server
system. All animal studies were conducted with the ap-
proval of Champions Oncology’s International Animal
Care and Use Committee (IACUC).
Patient-derived xenograft models at The Jackson
Laboratory
The Jackson Laboratory established each PDX model
using NSG (NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ) mice.
Tumor explants obtained from the patients were imme-
diately implanted into the rear flanks of recipient female
NSG (JAX # 5557) mice using a trochar. For tumors
reaching about 2000 mm3, they were collected and pas-
saged for serial transplantation in NSG mice to create
low-passage fragments or cohort for future studies. The
criteria for enrollment was the tumor volume range of
150–250mm3. Mice were treated with vehicle or ENT/
VCR as a single agent or combination at dose and route
of administration provided in Additional file 6: Table S1
until tumors reached 2000mm3 or reached study day 28.
The antitumor activity of ENT and VCR was tested. All
compounds were formulated according to the manufac-
turer’s specifications. Beginning day 0, tumor dimensions
were measured twice weekly by a digital caliper and data in-
cluding individual and mean estimated tumor volumes
(mean TV± SEM) recorded for each group; tumor volume
was calculated using the formula: TV = (width)2 × length/2.
All animal studies were conducted with the approval of
The Jackson Laboratory IACUC.
RNAseq
RNA sequencing was performed on four eRMS cultures
(human cell lines RD and Rh18, mouse cell cultures
U37125 and U57810). To identify transcriptional
changes in eRMS following ENT treatment, each sample
was treated with ENT for a fixed period of time along-
side a paired untreated sample. All samples were treated
for with ENT (2 μM) for 72 h. This dose was chosen
based on our previous publication [16] where murine
rhabdomyosarcoma primary tumor cell cultures were in-
cubated with varying concentration of ENT for 72 h.
The cytotoxic effect was then assessed by MTS assay.
All cells were cultured on 10-cm dishes, and treatment
began when plates were 60% confluent. Passages lower
than 7 were used for all mouse cultures. Bioinformatic
analysis of RNAseq performed as described in our earlier
study [14].
CRISPR screening in eRMS
Cell culture, sgRNA designs, and virus production
Murine eRMS tumor cell line (U57810) expressing
hCas9 was derived from retroviral transduction of
MSCV-hCas9-PGK-Puro vector into a parental U57810
cell line, followed by puromycin selection (1 μg/mL). All
sgRNAs were designed using http://crispr.mit.edu/ with
high-quality scores (> 70) to minimize off-target effects
and were subsequently cloned into U6-sgRNA-EFS-GFP
construct. HDAC sgRNAs were designed to specifically
target the deacetylase catalytic domains as previously de-
scribed [17]. Rosa26 and Rpa3 sgRNAs were used as
negative and positive controls, respectively. Lentiviral
sgRNA constructs were transfected together with viral
packaging vectors (pPAX2: VSVG) using the standard
protocol for PEI reagent (23966, Polysciences) into
HEK293T cells. Viral supernatants were collected be-
tween 24 to 48 h post-transfection and passed through a
0.45-μm filter.
sgRNA/GFP competition assays
To evaluate sgRNA effects on eRMS cell proliferation,
U57810 expressing Cas9 cells were transduced with
sgRNA virus, followed by flow cytometry analysis of
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GFP/sgRNA+ populations using a Guava Easycyte HT
instrument (Millipore) over a course of 16 days after
viral infection. GFP percentages at indicated time points
on histograms were normalized to day 2 GFP percent-
ages post-infection.
Statistical analysis
The statistical test used has been described in our previ-
ous study [14]. Briefly, in the case of the orthotopic
mouse model of murine eRMS, failure is defined as an
event for tumor size greater than or equal to 1.2 cm3.
Treatment groups were contrasted on the mean with
analysis of variance in log units. Time to event distribu-
tions were summarized with Kaplan-Meier curves, and
the significance of variation with the treatment group
was assessed with log-rank tests. Corrections for mul-
tiple comparisons were made with the Dunnett method
for ANOVA and with the Bonferroni method for
log-rank testing. Statistical testing on means and time to
event was two-sided with a nominal significance level of
5% and was carried out with R. The significance of vari-
ation intumor volume with treatment was assessed in
PDX models using a repeated-measureslinear model
with an autoregressive order 1 autocorrelation matrix
and a Tukey correction for multiple comparisons in
terms of treatment, day, and the treatment × day inter-
action. All statistical testing was two sidedwith a 5%
experiment-wise significance level and all analyses were
carried out in log10 units. SAS version 9.4 for Windows
(SAS Institute) was used throughout. Statistical signifi-
cance was set at *P < 0.05, **P < 0.01, and ***P < 0.001.
Error bars indicate mean ± SD or SEM.
Results
ENT in combination with vincristine slows eRMS tumor
growth and induces myodifferentiation in vivo
We tested the efficacy of ENT and VCR as single agents
and in combination in orthotopic allograft mouse models
of eRMS. eRMS does not harbor Pax3:Foxo1 fusion, and
thus, response was not expected to mimic fusion-positive
RMS [14]. The eRMS model was generated by injecting
murine eRMS primary cell cultures into the
cardiotoxin-preinjured gastrocnemius muscle of SHO
mice. ENT as a single agent showed minimal antitumor
activity in this embryonal model of RMS; however, in
these fusion-negative (Pax3:Foxo1 non-expressing) mice,
treatment with the combination of ENT plus VCR re-
duced tumor volume significantly (Fig. 1a, b).
Since combined treatment with ENT and VCR caused a
reduction in volumes of eRMS tumors (despite not carry-
ing Pax3:Foxo1 fusion gene), we investigated whether
treatment with ENT and VCR contributed to rhabdomyo-
blastic differentiation. Residual end-treatment tumors
were evaluated histologically, and rhabdomyoblastic
differentiation was scored for all the four treatment
groups. The percentage of rhabdomyoblasts in the tumors
from mice treated with the combination of ENT and VCR
was prominent (83% rhabdomyoblasts on average) com-
pared to mice treated with ENT alone (21%) or VCR alone
(20%). Representative histology of each treatment group is
provided in Fig. 1c. Mice bearing eRMS treated with the
combination of VCR and ENT had very few mitotic fig-
ures (3.5% mitotic figures on average) in comparison to
mice treated with VCR only (12%)—suggesting the
rhabdomyoblasts were quiescent or non-proliferative
rhabdomyoblasts (Additional file 1: Figure S1a-c).
These studies supported that eRMS tumor cells that
escaped cytoreduction were subject to rhabdomyo-
blastic differentiation—but only when ENT is com-
bined with a specific chemotherapeutic agent (VCR).
This result is consistent with clinical observations of
rhabdomyoblastic differentiation induced by treatment
stress [18].
ENT has single-agent activity in eRMS patient-derived
xenografts
We investigated the antitumor efficacy of ENT and VCR
as single agents and in combination for four biologically
independent patient-derived xenograft mouse models of
eRMS. The dosing details are given in Additional file 6:
Table S1a-b, and the PDX model characteristics are given
in Additional file 6: Table S2. Two of the four models were
from recurrent and/or metastatic tumors taken from a bi-
opsy or rapid autopsy. All of these contemporary models
were established after 2010. In half of the cases, ENT
showed single-agent activity in tumor growth inhibition
relative to control (Fig. 2a–d). These eRMS models were
hypersensitive to the VCR dose used in aRMS PDX
models; thus, the synergy between ENT and VCR could
not be assessed in this study. Statistical summaries of four
different PDX eRMS are given in Additional File 6: Table
S2-S6. Residual end-treatment tumors were examined his-
tologically, and rhabdomyoblastic differentiation was
scored for the CTG-1213 PDX mouse model. No differ-
ence existed between different treatment groups in terms
of rhabdomyoblast differentiation except for combination
(ENT + VCR) showing moderate differentiation (20%)
(Additional file 6: Table S7).
ENT has single-agent activity in PleoRMS patient-derived
tumorgraft xenografts
We next investigated the antitumor efficacy of ENT and
VCR as single agents and in combination in three bio-
logically independent patient-derived tumorgraft xeno-
graft mouse models of pleoRMS. PDX model
characteristics are given in Additional file 6: Table S8. In
all the cases, ENT had single-agent activity relative to
control (Fig. 2e–g). Statistical summaries of three
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different PDX pleoRMS models are given in Additional
file 6: Table S9-S11. Residual end-treatment tumors were
examined histologically, and rhabdomyoblastic differen-
tiation was scored for the CTG-800 PDX mouse model,
which showed the best response to treatment. There was
no difference seen between different treatment groups in
terms of rhabdomyoblast differentiation (Additional file 6:
Table S12). Representative histology of each treatment
group is provided in Additional file 2: Figure S2.
HDAC3 inhibition is responsible for tumor cell growth
inhibition in eRMS
Our recent study showed HDAC3 inhibition by ENT as
the primary mechanism in aRMS [14]. To determine
whether inhibition of a specific HDAC3 target of ENT
was responsible for cytoreduction in eRMS, we per-
formed CRISPR-Cas9-mediated targeting of the deacety-
lase domains of HDAC3 in the U57810 murine eRMS
primary tumor cell culture which were then tracked for
cell viability over 16 days. The HDAC3 CRISPR con-
structs reduced the viability of eRMS cells (Fig. 3a)
whereas other HDAC CRISPR did not reduce the cell
viability (Additional file 3: Figure S3a-d). These results
suggest that in eRMS, HDAC3 is a cell-autonomous sur-
vival factor. We have previously performed a cell viabil-
ity assay in murine eRMS culture, U57810 (in which we
carried out CRISPR-mediated depletion of HDAC3),
using entinostat. In U57810, a dose-dependent change in
cell viability at 72 h is present (IC25 1.2 μM; IC50
3.9 μM) (data not shown). By comparison, CRISPR
HDAC3 depletion in the same cell line showed a min-
imal effect at day 4 and a maximum effect at day 16.
These data are consistent and argue for a prolonged
time-dependent effect on cell viability in the
cell-autonomous experimental context.
To determine whether myogenic differentiation was a
cell-autonomous effect of ENT-VCR combination ther-
apy in eRMS, U57810 cells were treated with VCR and
ENT individually and in combination for 6 days.
RT-PCR measuring the mRNA expression of four differ-
ent muscle differentiation markers showed no apparent
differentiation effect in vitro (Additional file 3: Figure
S3e). In addition, we performed siRNA-mediated knock-
down of HDAC3 in eRMS cell line RD and analyzed for
Fig. 1 ENT treatment of eRMS in vivo. a Box-and-whisker plots showing the tumoristatic efficacy of entinostat in combination with vincristine in
eRMS mice (DMSO vs Ent + VCR. Data are presented as means ± SEM (N = 5 mice per cohort). ***P < 0.001 by log-rank test. b Kaplan-Meier plots
of eRMS mice treated with ENT at a daily dose of 5 mg/kg administered intraperitoneally, VCR at 1 mg/kg administered intraperitoneally once a
week or a combination of both. Treatment was stopped early for all mice after day 11 because of body weight loss in some of the animals. Data
are presented as means ± SEM (N = 5 mice per cohort). ***P < 0.001 by log-rank test. c Samples were collected from mice upon necropsy at study
completion. Tumors were stained by hematoxylin and eosin and scored blindly. Rhabdomyoblasts are visible in ENT + VCR treated cells (pointed
with white arrowhead). Scale bar, 100 μM
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the protein expression of terminal differentiation marker,
myosin heavy chain (MHC). We used differentiated hu-
man myoblasts as the positive control. Analysis of MHC
expression using anti-My3 antibody showed MHC ex-
pression in the lane for differentiated HSMM. However,
we did not detect MHC expression in RD cells depleted
of HDAC3. In addition to eRMS cell line, we also ana-
lyzed aRMS cell line Rh30 depleted of HDAC3 for MHC
expression. The result is similar to the eRMS cell line
with no induced expression of MHC upon depletion of
HDAC3 (Additional file 4: Figure S4). This is in contra-
distinction to the observed significant in vivo change in
rhabdomyoblast counts for this murine eRMS model.
This difference between in vitro and in vivo results raises
the possibility that species-specific tumor microenviron-
ment factors are critical to the myodifferentiation effect
observed in vivo factors that may have been present in
allografts but not xenografts.
Fig. 2 In vivo evaluation of ENT and VCR in eRMS and pleoRMS patient-derived xenograft. a–g Graphical analysis of four different PDX eRMS and
three different PDX pleoRMS mice models (Champions Oncology and The Jackson Laboratory) established from clinical biopsies, recurrent eRMS,
or autopsies male/female with eRMS. Detailed patient history of these eRMS and pleoRMS models is given in Additional file 6: Table S2 & S8
respectively. Mice were treated with vehicle, ENT (4 mg/kg or 5 mg/kg), and vincristine (0.75 mg/kg) as single agents and in combination in each
treatment groups and average tumor volume were plotted until the end-point of the experiment. Detailed treatment schedules are given in
Additional file 6: Table S1. Statistical summary for the response to treatment is given in Additional file 6: Table S4–S6 for eRMS PDX models and in
Additional file 6: Table S9–S11 for pleoRMS. Effectiveness of VCR precluded drawing any conclusions of ENT-VCR combination therapy in eRMS models
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Transcriptional reprogramming by ENT differs for aRMS
versus eRMS
We next turned to short-term RNAseq in order to explore
whether ENT induced tumor cell production of factors
related to remodeling the tumor microenvironment. We
have previously shown that tumor cells can interact with
muscle stem cells (i.e., satellite cells) in an
IL-4R-dependent manner to accelerate tumor progression
[19]. An integrated dataset was constructed for eRMS
consisting of differential expression data and HDAC1, 2,
3, or 11 binding data (Fig. 3b). This merged dataset identi-
fied several genes of interest. To understand the broad
changes in the transcriptional program for eRMS due to
ENT treatment, Gene Ontology analysis [20] was carried
out using PANTHER version 14.0 to identify key upregu-
lated or downregulated processes. This ontology analysis
of eRMS identified several key upregulated muscular pro-
grams: muscle contraction, muscle system process, muscle
organ development, muscle structure development, and
cell differentiation (Additional file 7: Table S14), which
surprisingly does not translate into in vitro myodifferentia-
tion as seen in vivo with the possibility that tumor micro-
environment factors are critical to the myodifferentiation
effect observed in vivo in response to ENT treatment.
However, more prominent than any other feature of
ENT-regulated genes was the cohort of cytokine (CCL2,
CSF1, CXCL1), growth factor (IGF2), and extracellular
matrix genes (ECM1, SERPINE1) (Fig. 3b). These factors
are associated with both myoblast/myofiber communica-
tion and differentiation [21] and macrophage interactions
[22]. However, when re-examining ENT-VCR-treated
mice, macrophage infiltration was increased only in areas
of necrosis, not elsewhere. No difference in macrophage
infiltration was observed between treatment groups (Add-
itional file 5: Figure S5). Taken together, these results sug-
gest that following cell-autonomous tumor cell death
caused by HDAC3 inhibition, residual tumor cells under
chemotherapeutic stress are induced to express cytokines
and growth factors. These secreted factors may in turn
lead to non-macrophage tumor microenvironment inter-
actions facilitating rhabdomyoblastic differentiation of ad-
jacent tumor cells.
Discussion
Our previous study uncovered that cell of origin epige-
netically influenced transcription of the PAX3:FOXO1
oncogene in fusion-positive RMS [16]. This observation
led to the investigation of pharmacological modifiers of
Fig. 3 CRISPR/Cas9 mediated HDAC3 inhibition and evaluation of tumor cell growth inhibition in eRMS and HDAC1/2/3/11 binding data for key
ENT-treated eRMS samples. a CRISPR/Cas9 screen for the viability of selected HDAC3 excision by CRISPR in murine eRMS. b RNA from four human
and murine eRMS cultures (U37125 in two replicates, U57810, RD, RH18) were sequenced following ENT treatment at 2 μM for 72 h and compared
against DMSO-treated cultures. Rh18 which was hypersensitive to ENT and was only treated for 24 h. Key hits were identified as those overexpressed
(log2 ratio of ENT expression divided by control expression > 1) in all samples
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transcription of the fusion protein via HDAC inhibition.
ENT, a potent and selective Class I HDAC inhibitor, re-
duced the abundance of the tumor-driving PAX3:FOXO1
mRNA and protein expression [14]. Further investigation
revealed HDAC3-SMARCA4-miR-27a-PAX3:FOXO1 cir-
cuit as a critical driver of chemo-resistant fusion-positive
RMS [14]. The purpose of the current study was to inves-
tigate the preclinical efficacy of ENT in the other and
more common subtype, eRMS [23]. ENT in combination
with the chemotherapy agent VCR showed strong antitu-
mor activity in eRMS orthotopic mouse models, antitu-
mor activity in eRMS PDX models as a single agent in half
of the cases, and a range of single-agent activity in
pleoRMS PDX models. Although our in vitro concentra-
tion of ENT was higher at 400 nM and 2000 nM, our pre-
clinical dose in eRMS and pleoRMS PDX models were
clinically comparable (or slightly under-dosed) and similar
to our recent study of ENT in aRMS [14]. In addition, the
concentration of 400 nM used in vitro was less than the
reported highest achievable maximum drug serum con-
centration (Cmax) for ENT of 1000 nM [24], and the 2000
nM concentration was comparable to the very maximum
dose of ENT used in our previous study [14] to see a
dose-dependent effect of ENT in fusion-positive RMS.
Our CRISPR studies of the HDAC targets of ENT sug-
gest that HDAC3 is a key factor to eRMS
cell-autonomous tumor cell survival. Following cytore-
duction in vivo in orthotopic allografts, residual tumor
cells treated with chemotherapy undergo a dramatic,
ENT-induced (70–100%) conversion to non-proliferative
rhabdomyoblasts, raising the possibility that myogenic
differentiation could be a true therapeutic goal [25].
Rhabdomyoblasts remaining at the end of multimodal
therapy rarely if ever lead to disease recurrence and may
truly represent a differentiated state [26]. Our studies
further narrow the mechanism of this effect to the po-
tential interplay of tumor cells secreting cytokines and
non-malignant cells and the tumor microenvironment to
cause this tumor cell differentiation. In eRMS PDX
models, cytoreduction was a consistent feature, but myo-
genic differentiation was noticeably absent. This result is
in contrast to the recently published work, which
showed that HDAC3 knockout arrests tumor growth
and induces myogenic differentiation both in vitro and
in vivo [27].
Conclusion
In summary, our data suggest that targeting Class I
HDACs may provide a therapeutic benefit for patients
with eRMS. The single agent preclinical in vivo efficacy of
ENT begets exploration of a combination with chemo-
therapy in a clinical trial for eRMS—although our studies
of PDX models had too strong of VCR single-agent activ-
ity to detect synergy. The synergy in vivo of ENT in
combination with chemotherapy for fusion-negative
eRMS orthotopic allograft models and unexpected myo-
differentiation effect brings new possibilities that epigen-
etic modifiers can not only cytoreduce tumors but also
reprogram cancer cells towards a non-tumorigenic cell
fate as a desired therapeutic outcome.
Additional files
Additional file 1: Figure S1. Phosphohistone H3 (pHH3) expression and
rhabdomyoblast count in VCR and ENT + VCR-treated eRMS. (a) pHH3 ex-
pression of eRMS mouse tumor (animal id: 67833) after treatment with
single agent VCR. Scale Bar: 50 μM. (b) pHH3 expression of eRMS mouse
tumor (animal id: 67822) after treatment with both ENT and VCR. Scale
bar: 50 μM (c) Histological scoring of various mouse eRMS after four dif-
ferent types of treatment; DMSO, VCR, ENT, or a combination of ENT and
VCR (ENT + VCR). Counted all fields 500 to 3000 cells under low and
higher magnification on each slide. This count excluded endothelial cells
and inflammatory cells. * denotes not determined while ** denotes myo-
globin was immunohistochemically positive. (TIF 2381 kb)
Additional file 2: Figure S2. Representative histology of CTG-800
PDX mouse pleoRMS rhabdomyosarcoma tissue. Tumors were stained
by hematoxylin and eosin and scored blindly. Scale Bar, 100 μM.
(TIF 2568 kb)
Additional file 3: Figure S3. CRISPR/Cas9 mediated HDACs inhibition
and evaluation of tumor cell growth inhibition in eRMS. (a-e) CRISPR/Cas9
screen for viability of selected HDACs (HDAC1-2 & HDAC10-11) excision
by CRISPR in murine eRMS. (f) Q-PCR of murine eRMS U57810 for the ex-
pression of myogenic markers of differentiation in vitro. Data normalized
to GAPDH expression. Gene expression was quantified using 2−^dCt
method. Myogenin (MYOG), Myoblast determination protein 1 (MyoD)
and Myoglobin (Mb). (TIF 2070 kb)
Additional file 4: Figure S4. siRNA-mediated knockdown of HDAC3 in
eRMS and aRMS. Analysis of MHC expression in RD, Rh30 and HSMM cell
lines transfected with siRNA at 100 nM for 72 h, targeting HDAC3. (TIF 510
kb)
Additional file 5: Figure S5. Representative immunohistochemistry for
CD68 of mouse eRMS tissue and primary cells. Necrotic tissue (a) showed
few macrophages present, while viable tumor (b) showed a collection of
many macrophages. Macrophage presence was observed as being the
same for all treatment groups. (TIF 2929 kb)
Additional file 6: Table S1. Treatment schedule for PDX models. Table
S2. Patient history of PDX eRMS models. Table S3. Statistical summary
for CTG-1213/POS-13212. Table S4. Statistical summary for CTG1116/
POS-13166. Table S5. Statistical summary for CTG-1628/POS-132166B.
Table S6. Statistical summary for J0103366/CF-13A. Table S7. Histological
markers of differentiation in PDX eRMS (CTG-1213) mice. Table S8. Pa-
tient history of PDX pleoRMS models. Table S9. Statistical summary for
CTG-1213/POS-13212. Table S10. Statistical summary for CTG1116/POS-
13166. Table S11. Statistical summary for CTG-1628/POS-132166B.
Table S12. Histological markers of differentiation in PDX pleoRMS
(CTG-800) mice. Table S13. Primers for RT-PCR. (DOCX 41 kb)
Additional file 7: Table S14. Gene ontology analysis. (XLSX 62 kb)
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